Parkinson’s disease has no cure, but ibogaine may be quietly rewriting what’s possible for the 11 million people living with it.
Today on Ibogaine Uncovered, Talia Eisenberg talks with Tobias Erny, a researcher and practitioner with nearly two decades of experience working with iboga, about the science, the stories, and the honest limits of this emerging therapy.
They cover the case of Patient D, whose motor function transformed after ibogaine treatment; the published case report documenting 50%+ improvements across motor, mood, and quality-of-life measures; the pharmacology behind why it might work; low-dose protocols; who responds and who doesn’t; complementary lifestyle support; and how to pursue this path safely and responsibly.
Tobias Erny is trained in the chemical and pharmaceutical industry and works at the intersection of neuroscience, lived clinical experience, and psychedelic science.
He is a lead author on one of the first published case reports exploring ibogaine for Parkinson’s disease, and is developing a placebo-controlled clinical trial with the University of Zurich.
Timestamps
(04:00) What Parkinson’s disease actually is: dopamine loss, stages, and progression
(07:00) Environmental toxins and elevated Parkinson’s risk in farming and golf course communities
(10:00) The pharmacology of iboga: GDNF, dopamine transporter chaperoning, and antidepressant effects
(16:00) The published case study: 80 days, five validated instruments, 50%+ improvements
(23:00) Who responds and who doesn’t, and plans for a clinical trial in Zurich
(27:00) Complementary support: movement, nutrition, sleep, and lifestyle
(31:00) Safety, sourcing risks, medical screening, and setting honest expectations
